ASKA Aims for 50% Share of Generic Candesartan Market through Blopress AG: President

ASKA President Takashi Yamaguchi ASKA Pharmaceutical President Takashi Yamaguchi showed on November 25 his enthusiasm for obtaining a 50% share of the candesartan generic market through its authorized generic (AG) of Takeda Pharmaceutical’s Blopress (candesartan). “We hope to establish the...read more